PMID- 17952581
OWN - NLM
STAT- MEDLINE
DCOM- 20080215
LR  - 20181201
IS  - 0920-3206 (Print)
IS  - 0920-3206 (Linking)
VI  - 21
IP  - 6
DP  - 2007 Dec
TI  - Levosimendan improves renal function in patients with acute decompensated heart 
      failure: comparison with dobutamine.
PG  - 431-5
AB  - BACKGROUND: Levosimendan is a relatively new cardiac inotropic agent with calcium 
      sensitizing activity. This study was conducted to investigate the effects of 
      levosimendan (L) and dobutamine (D) on renal function in patients hospitalized 
      with decompensated heart failure (HF). METHOD: The present study included 88 
      consecutive patients hospitalized with acutely decompensated HF (New York Heart 
      Association (NYHA) Class 3-4) requiring inotropic therapy. Patients were 
      randomized 2:1 to either L or D for intravenous inotropic support. Diuretic 
      therapy was kept constant during infusions. Renal function values, including 
      serum creatinine (CR), blood urea nitrogen, 24-h urinary output levels and 
      calculated glomerular filtration rate (GFR) were measured just prior to and 24 h 
      after the infusions in all patients, and 48 and 72 h after the infusions in every 
      second patient in both groups. The pre and post-infusion values of renal function 
      and left ventricular ejection fraction (LVEF) were evaluated. RESULTS: LVEF 
      increased significantly in both groups. Those in L showed a significant 
      improvement in calculated GFR after 24 h, whereas those in D showed no 
      significant change (median in change in L:+15.3%, median change in D: -1.33%). 
      Furthermore, in the L group a significant improvement was observed in calculated 
      GFR after 72 h compared to baseline levels, whereas in D no significant change 
      (median change in L:+45.45%, median change in D: +0.09%) was seen. Both agents 
      improved 24-h urinary output. CONCLUSION: Levosimendan seems to provide 
      beneficial effects in terms of improvement in renal function compared to 
      dobutamine in patients with heart failure who require inotropic therapy.
FAU - Yilmaz, Mehmet Birhan
AU  - Yilmaz MB
AD  - Department of Cardiology, Cumhuriyet University Faculty of Medicine, 584140, 
      Sivas, Turkey. cardioceptor@gmail.com
FAU - Yalta, Kenan
AU  - Yalta K
FAU - Yontar, Can
AU  - Yontar C
FAU - Karadas, Filiz
AU  - Karadas F
FAU - Erdem, Alim
AU  - Erdem A
FAU - Turgut, Okan Onur
AU  - Turgut OO
FAU - Yilmaz, Ahmet
AU  - Yilmaz A
FAU - Tandogan, Izzet
AU  - Tandogan I
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20071020
PL  - United States
TA  - Cardiovasc Drugs Ther
JT  - Cardiovascular drugs and therapy
JID - 8712220
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Hydrazones)
RN  - 0 (Pyridazines)
RN  - 349552KRHK (Simendan)
RN  - 3S12J47372 (Dobutamine)
SB  - IM
CIN - Cardiovasc Drugs Ther. 2007 Dec;21(6):403-4. PMID: 18030611
MH  - Acute Disease
MH  - Aged
MH  - Cardiotonic Agents/*pharmacology
MH  - Dobutamine/*pharmacology
MH  - Female
MH  - Glomerular Filtration Rate/drug effects
MH  - Heart Failure/*drug therapy/physiopathology
MH  - Humans
MH  - Hydrazones/*pharmacology
MH  - Kidney/*drug effects/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Pyridazines/*pharmacology
MH  - Simendan
MH  - Urination/drug effects
EDAT- 2007/10/24 09:00
MHDA- 2008/02/19 09:00
CRDT- 2007/10/24 09:00
PHST- 2007/08/15 00:00 [received]
PHST- 2007/10/08 00:00 [accepted]
PHST- 2007/10/24 09:00 [pubmed]
PHST- 2008/02/19 09:00 [medline]
PHST- 2007/10/24 09:00 [entrez]
AID - 10.1007/s10557-007-6066-7 [doi]
PST - ppublish
SO  - Cardiovasc Drugs Ther. 2007 Dec;21(6):431-5. doi: 10.1007/s10557-007-6066-7. Epub 
      2007 Oct 20.